Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qlife Holding ABOSTO:QLIFE +0.54%13 Debt-to-Equity is 4.58 as of Mar. 2026, which is 11350% above its 10-year median of 0.04. GuruFocus rates OSTO:QLIFE with a GF Score™ of 13/100 and a GF Value™ of kr0.74 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 703 Medical Devices & Instruments companies, Qlife Holding AB ranks worse than 97.58% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Qlife Holding AB's Debt-to-Equity or its related term are showing as below:
OSTO:QLIFE'
s Debt-to-Equity Range Over the Past 10 Years
Min: -23.7 Med: 0.04 Max: 43.13
Current: 4.58
During the past 7 years, the highest Debt-to-Equity Ratio of Qlife Holding AB was 43.13. The lowest was -23.70. And the median was 0.04.
OSTO:QLIFE's Debt-to-Equity is ranked worse than 97.58% of 703
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs OSTO:QLIFE: 4.58
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Qlife Holding AB Debt-to-Equity Related Terms
Qlife Holding AB Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Qlife Holding AB's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:QLIFE vs ABT, SYK, MDT: Debt-to-Equity Comparison
For the Medical Devices subindustry, Qlife Holding AB's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qlife Holding AB Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Qlife Holding AB's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Qlife Holding AB's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qlife Holding AB (OSTO:QLIFE) has a Debt-to-Equity of 4.58 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Qlife Holding AB and its competitors. This is 11350% above median its historical median of 0.04. According to the industry distribution chart, Qlife Holding AB ranks #686 out of 703 companies in the Medical Devices & Instruments industry, placing it in the top 97.6%.
Is Qlife Holding AB's Debt-to-Equity too high?
Qlife Holding AB's current Debt-to-Equity of 4.58 is 11350% above median its 10-year median of 0.04. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Qlife Holding AB's value of 4.58 is 1891.3% above this industry median. Based on the distribution chart, Qlife Holding AB ranks #686 out of 703 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Qlife Holding AB has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Qlife Holding AB's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Qlife Holding AB ranks #686 out of 703 companies for Debt-to-Equity. This places Qlife Holding AB in the lower half of its industry. The industry median Debt-to-Equity is 0.23. Qlife Holding AB's value of 4.58 is 1891.3% above this benchmark. While the company's 10-year median is 0.04 vs. the industry median of 0.23, Qlife Holding AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 703 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qlife Holding AB's current Debt-to-Equity of 4.58 is 1891.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Qlife Holding AB and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qlife Holding AB's current Debt-to-Equity is 4.58, which is 11350% above median its own 10-year median of 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qlife Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Qlife Holding AB (OSTO:QLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.74, compared to a current price of kr1.88 — trading 153.5% above its estimated fair value. The current Debt-to-Equity is 4.58, which is 11350% above median its 10-year median of 0.04 and 1891.3% above the Medical Devices & Instruments industry median of 0.23. Qlife Holding AB's overall GF Score™ is 13/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Qlife Holding AB (OSTO:QLIFE), the current Debt-to-Equity is 4.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qlife Holding AB (OSTO:QLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Qlife Holding AB stock appears to be overvalued.
The current stock price of kr1.88 is trading 153.5% above its estimated GF Value™ of kr0.74.
GuruFocus considers Qlife Holding AB to be Significantly Overvalued.
Key valuation signals for OSTO:QLIFE:
Debt-to-Equity: 4.58 (11350% above median its 10-year median of 0.04)
GF Value™: kr0.74 vs. price of kr1.88 (153.5% above fair value)
Industry Position: 1891.3% above the Medical Devices & Instruments median (#686 of 703)
No single metric tells the full story. See the OSTO:QLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qlife Holding AB is a medical device company that seeks to revolutionize the clinical biomarker testing of whole blood by taking it out of the lab and into the homes of the people who needs it. The Egoo Home System is an integrated platform consisting of a small home device and disposable capsules, each of which tests for a specific biomarker. It provides a digital infrastructure for sharing the data with the patient's doctor, clinic or hospital via smartphone and computer.
13GF Score
Get the complete analysis for OSTO:QLIFE
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:QLIFE has been successfully added to your 
